Suppr超能文献

单剂量口服泼尼松龙与口服地塞米松治疗喉炎的比较:一项随机对照试验。

Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized-controlled trial.

作者信息

Asif Alvina, Tayyab Asma, Qazi Shaista, Zulfqar Rubina, Hussain Irshad, Mumtaz Hassan

机构信息

Islamabad Medical and Dental College.

KRL Hospital Islamabad.

出版信息

Ann Med Surg (Lond). 2023 Apr 7;85(5):1379-1384. doi: 10.1097/MS9.0000000000000420. eCollection 2023 May.

Abstract

UNLABELLED

Croup is a common respiratory illness in children, accounting for 15% of annual clinic and emergency department visits for pediatric respiratory tract infections. We aimed to compare single-dose oral prednisolone with single-dose oral dexamethasone in the treatment of croup in terms of mean change in the Westley Croup Score.

SETTING

Emergency Department of Children Hospital.

DURATION

Six months from December 2017 to June 2022.

DESIGN

Randomized-controlled trial.

SUBJECTS AND METHODS

A total of 226 children with Westley Croup Score 2 or more were included in this study. Patients were randomized into two groups, 113 patients received a single dose of 0.15 mg/kg of oral dexamethasone, while 113 patients received a single dose of 1 mg/kg of oral prednisolone. Croup score and other clinical observations were repeated at 4 h and recorded in the questionnaire.

RESULTS

The average age of the patients was 2.88±1.17 years. There were 129 (57.1%) males and 97 (42.9%) females. At 4 h, a significant reduction in mean Westley Croup Score was observed in group dexamethasone as compared with group prednisolone (=0.0005).

CONCLUSIONS

Our trial demonstrated that oral dexamethasone at a dose of 0.15 mg/kg is effective in reducing the total croup score but there were no statistical differences in respiratory rate, pulse rate, and oxygen saturation between groups. Future studies are required to determine if these treatments differ in efficacy for severe croup and whether there is a role for multiple-dose corticosteroid therapy in some patients.

摘要

未标注

哮吼是儿童常见的呼吸道疾病,占儿科呼吸道感染年度门诊和急诊科就诊人次的15%。我们旨在比较单剂量口服泼尼松龙与单剂量口服地塞米松在治疗哮吼方面的韦氏哮吼评分平均变化。

研究地点

儿童医院急诊科。

持续时间

2017年12月至2022年6月共6个月。

设计

随机对照试验。

研究对象与方法

本研究共纳入226例韦氏哮吼评分2分及以上的儿童。患者被随机分为两组,113例患者接受单剂量0.15mg/kg的口服地塞米松,而113例患者接受单剂量1mg/kg的口服泼尼松龙。哮吼评分和其他临床观察在4小时时重复进行,并记录在问卷中。

结果

患者的平均年龄为2.88±1.17岁。男性129例(57.1%),女性97例(42.9%)。在4小时时,与泼尼松龙组相比,地塞米松组的平均韦氏哮吼评分显著降低(P=0.0005)。

结论

我们的试验表明,剂量为0.15mg/kg的口服地塞米松在降低哮吼总分方面有效,但两组之间的呼吸频率、脉搏率和血氧饱和度无统计学差异。未来需要进行研究,以确定这些治疗方法在重症哮吼的疗效上是否存在差异,以及多剂量皮质类固醇疗法在某些患者中是否有作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b0c/10205353/4bcbab08cc7a/ms9-85-1379-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验